- This event has passed.
Event Date: April 1, 2020, 12:00-1:00 PM ET
Registration Deadline: March 31, 2020 11:59 PM ET
Member: $15 | Nonmember: $75
This course is approved for 1.0 ACRP contact hours. Accreditation Details
Member: $0 | Nonmember: N/A
In oncology clinical trials, assessment of changes in tumor burden is a primary endpoint. For solid tumors, RECIST 1.1 is the established criteria. However, as we move from chemotherapeutic trials into immunotherapeutic trials, a new response to treatment pattern has become evident. A subset of patients to have increased tumor burden that is followed by a clear response or prolonged stabilization of the cancer. iRECIST guidelines have been developed to capture this new response pattern.Part 1 of 2 presentations introduced you to the history of the iRECIST guidelines, the iRECIST process and how iRECIST is being used in oncology clinical trials. This Webinar, Part 2, will consist of a workshop using hypothetical cases to determine iRECIST responses.
Upon completion of this webinar, attendees will be able to:
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.